IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10538532 B1

PDFFull Text
Date of Patent:
Jan. 21, 2020

Filed:

Nov. 19, 2018

Hepatitis b antiviral agents

Applicant:

Enanta Pharmaceuticals, Inc., Watertown, MA (US);

Inventors:

Yao-Ling Qiu, Andover, MA (US);

Xuri Gao, Newtonville, MA (US);

Wei Li, Lexington, MA (US);

Hui Cao, Belmont, MA (US);

Meizhong Jin, Wellesley, MA (US);

Jorden Kass, Arlington, MA (US);

Xiaowen Peng, Sudbury, MA (US);

Yat Sun Or, Waltham, MA (US);

Assignee:

Enanta Pharmaceuticals, Inc., Watertown, MA (US);

Attorneys:

Edgar W. Harlan

Carolyn S. Elmore

Elmore Patent Law Group, P.C.

Primary Examiner:

Zinna Northington Davis

Int. Cl.
CPC ...
C07D 493/08 (2006.01); A61K 31/167 (2006.01); A61K 31/18 (2006.01); A61K 31/196 (2006.01); A61K 31/215 (2006.01); A61K 31/223 (2006.01); A61K 31/277 (2006.01); A61K 31/325 (2006.01); A61K 31/335 (2006.01); A61K 31/336 (2006.01); A61K 31/341 (2006.01); A61K 31/351 (2006.01); A61K 31/357 (2006.01); A61K 31/365 (2006.01); A61K 31/39 (2006.01); A61K 31/401 (2006.01); A61K 31/41 (2006.01); A61K 31/415 (2006.01); A61K 31/416 (2006.01); A61K 31/4164 (2006.01); A61K 31/421 (2006.01); A61K 31/426 (2006.01); A61K 31/439 (2006.01); A61K 31/44 (2006.01); A61K 31/4402 (2006.01); A61K 31/4409 (2006.01); A61K 31/4425 (2006.01); A61K 31/445 (2006.01); A61K 31/4545 (2006.01); A61K 31/5377 (2006.01); A61K 31/655 (2006.01); C07B 59/00 (2006.01); C07C 235/56 (2006.01); C07C 311/53 (2006.01); C07C 317/32 (2006.01); C07C 323/42 (2006.01); C07D 207/16 (2006.01); C07D 211/54 (2006.01); C07D 213/52 (2006.01); C07D 213/81 (2006.01); C07D 213/89 (2006.01); C07D 231/12 (2006.01); C07D 233/64 (2006.01); C07D 257/04 (2006.01); C07D 261/02 (2006.01); C07D 261/08 (2006.01); C07D 261/20 (2006.01); C07D 263/52 (2006.01); C07D 277/26 (2006.01); C07D 295/088 (2006.01); C07D 303/26 (2006.01); C07D 303/34 (2006.01); C07D 307/32 (2006.01); C07D 307/33 (2006.01); C07D 309/08 (2006.01); C07D 313/04 (2006.01); C07D 317/72 (2006.01); C07D 327/10 (2006.01); C07D 401/04 (2006.01); C07D 451/04 (2006.01); C07D 493/04 (2006.01); C07C 317/44 (2006.01); C07C 323/62 (2006.01);
U.S. Cl.
CPC ...
C07D 493/08 (2013.01); A61K 31/167 (2013.01); A61K 31/18 (2013.01); A61K 31/196 (2013.01); A61K 31/215 (2013.01); A61K 31/223 (2013.01); A61K 31/277 (2013.01); A61K 31/325 (2013.01); A61K 31/335 (2013.01); A61K 31/336 (2013.01); A61K 31/341 (2013.01); A61K 31/351 (2013.01); A61K 31/357 (2013.01); A61K 31/365 (2013.01); A61K 31/39 (2013.01); A61K 31/401 (2013.01); A61K 31/41 (2013.01); A61K 31/415 (2013.01); A61K 31/416 (2013.01); A61K 31/4164 (2013.01); A61K 31/421 (2013.01); A61K 31/426 (2013.01); A61K 31/439 (2013.01); A61K 31/44 (2013.01); A61K 31/4402 (2013.01); A61K 31/445 (2013.01); A61K 31/4409 (2013.01); A61K 31/4425 (2013.01); A61K 31/4545 (2013.01); A61K 31/5377 (2013.01); A61K 31/655 (2013.01); C07B 59/001 (2013.01); C07C 235/56 (2013.01); C07C 311/53 (2013.01); C07C 317/32 (2013.01); C07C 317/44 (2013.01); C07C 323/42 (2013.01); C07C 323/62 (2013.01); C07D 207/16 (2013.01); C07D 211/54 (2013.01); C07D 213/52 (2013.01); C07D 213/81 (2013.01); C07D 213/89 (2013.01); C07D 231/12 (2013.01); C07D 233/64 (2013.01); C07D 257/04 (2013.01); C07D 261/02 (2013.01); C07D 261/08 (2013.01); C07D 261/20 (2013.01); C07D 263/52 (2013.01); C07D 277/26 (2013.01); C07D 295/088 (2013.01); C07D 303/26 (2013.01); C07D 303/34 (2013.01); C07D 307/32 (2013.01); C07D 307/33 (2013.01); C07D 309/08 (2013.01); C07D 313/04 (2013.01); C07D 317/72 (2013.01); C07D 327/10 (2013.01); C07D 401/04 (2013.01); C07D 451/04 (2013.01); C07D 493/04 (2013.01); C07B 2200/05 (2013.01); C07B 2200/07 (2013.01); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/14 (2017.05); C07C 2601/16 (2017.05); C07C 2601/18 (2017.05); C07C 2602/44 (2017.05); C07C 2602/46 (2017.05); C07C 2603/74 (2017.05);
Abstract

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:X-A-Y-L-R  (I)which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Find Patent Forward Citations

Loading…